KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) EBITDA (2017 - 2026)

Twist Bioscience has reported EBITDA over the past 10 years, most recently at -$44.1 million for Q1 2026.

  • Quarterly EBITDA fell 12.12% to -$44.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$81.3 million through Mar 2026, up 57.49% year-over-year, with the annual reading at -$77.8 million for FY2025, 62.7% up from the prior year.
  • EBITDA was -$44.1 million for Q1 2026 at Twist Bioscience, down from -$30.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $20.2 million in Q2 2025 and troughed at -$85.6 million in Q2 2024.
  • The 5-year median for EBITDA is -$44.1 million (2026), against an average of -$43.6 million.
  • Year-over-year, EBITDA tumbled 62.41% in 2022 and then soared 123.57% in 2025.
  • A 5-year view of EBITDA shows it stood at -$43.1 million in 2022, then grew by 0.56% to -$42.8 million in 2023, then grew by 25.91% to -$31.7 million in 2024, then grew by 4.0% to -$30.5 million in 2025, then tumbled by 44.79% to -$44.1 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's EBITDA are -$44.1 million (Q1 2026), -$30.5 million (Q4 2025), and -$26.9 million (Q3 2025).